(Abstracted from JAMA 2018;320:43–52)
There are only limited data in North American populations on the relative diagnostic effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared with cytology.
Faculty of Medicine, University of British Columbia (G.S.O., M.K., D.Q., R.E.M., G.C.E.S.); British Columbia Centre for Disease Control (G.S.O., M.K., D.C.); Lower Mainland Laboratories (D.v.N.); Cervical Cancer Screening Program, British Columbia Cancer (D.v.N., L.W.S., D.C., L.G., K.C., M.L., L.G., A.J.C.); Cancer Control Research, BC Cancer (S.P.); Canadian Centre for Applied Research in Cancer Control (S.P.), Vancouver; Faculty of Health Sciences, Simon Fraser University, Burnaby (S.P.), British Columbia; and Departments of Oncology and Epidemiology & Biostatistics, McGill University, Montreal, Quebec (E.L.F.), Canada